MingDu Intelligent Snares ￥80M in Series A+ Round

According to 36Kr.com, MingDu Intelligent, a medical intelligent manufacturing service provider for pharmaceutical companies, announced the completion of ￥80 million Series A+ round, led by Zheshang Venture Capital, with participation from China Merchants Venture Capital and Topping Capital. The funds raised will mainly be used for market expansion and product development and upgrade.

Focusing on the pharmaceutical industry, MingDu Intelligent provides large pharmaceutical firms with digital transformation services from R&D to production, storage and logistics. Based on big data and AI technology, MingDu Intelligent has launched the R&D management software called "SmartLab" to help customers scientifically manage their pipelines, making it more convenient for R&D personnel to carry out research, so as to improve the efficiency of drug certification.

In terms of production, MingDu Intelligent has developed the medical intelligent system based on industrial IoT technology, including electronic batch record (EBR), batch traceability, etc., to help companies in the compliance management, process and quality, and other aspects and store industrial big data, thus to provide the decision of technology, management, and quality improvement.

At the logistics end, MingDu Intelligent helps clients to build the intelligent warehousing system between warehousing and production, realize the automatic storage and intelligent control and the serialization of drugs with "one item, one code" by using the blockchain technology.

Wei Wei, CTO of MingDu Intelligent, said that for a long time, the pharmaceutical industry has made slow progress in informatization and intelligent construction. Compared with the United States, the European Union, Japan and others, China's pharmaceutical industry has great room for improvement in the digital upgrading of pharmaceutical enterprise, compliance management and other aspects. Especially after the introduction of a series of policies, the digitalized and intelligent transformation of drug R&D and production has become an inevitable choice for pharmaceutical companies.

ZSVC has currently managed more than 30 VC/PE funds, NEEQ funds, private placement funds, mergers and acquisitions funds, with AUM of approximately 40 billion yuan. ZSVC mainly invested in big health, big consumption, new economy, new manufacturing and other fields.

Headquartered in both Shenzhen and Hong Kong, CMC was founded in 2012 with registered capital of US$160 Million. As the subsidiary of China Merchants Group ("CM Group"), CMC is the investment management platform of it, specializing in alternative investments and management.